These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30701022)

  • 1. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.
    Pozo K; Zahler S; Ishimatsu K; Carter AM; Telange R; Tan C; Wang S; Pfragner R; Fujimoto J; Grubbs EG; Takahashi M; Oltmann SC; Bibb JA
    Oncotarget; 2018 Dec; 9(102):37662-37675. PubMed ID: 30701022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
    Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
    J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of vandetanib in the management of medullary thyroid cancer.
    Brassard M; Rondeau G
    Biologics; 2012; 6():59-66. PubMed ID: 22500115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
    Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.
    Broutin S; Commo F; De Koning L; Marty-Prouvost B; Lacroix L; Talbot M; Caillou B; Dubois T; Ryan AJ; Dupuy C; Schlumberger M; Bidart JM
    Thyroid; 2013 Jul; ():. PubMed ID: 23822199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
    Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.
    Lodish M; Gkourogianni A; Bornstein E; Sinaii N; Fox E; Chuk M; Marcus L; Akshintala S; Balis F; Widemann B; Stratakis CA
    Int J Pediatr Endocrinol; 2015; 2015(1):3. PubMed ID: 25972901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
    Giunti S; Antonelli A; Amorosi A; Santarpia L
    Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Updates on the Management of Medullary Thyroid Carcinoma.
    Kim BH; Kim IJ
    Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
    Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
    J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances and controversies in the management of medullary thyroid carcinoma.
    Maia AL; Wajner SM; Vargas CV
    Curr Opin Oncol; 2017 Jan; 29(1):25-32. PubMed ID: 27792051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating medullary thyroid cancer in the age of targeted therapy.
    Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
    Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
    Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
    Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission of Ectopic Cushing Syndrome Secondary to Medullary Thyroid Cancer With Vandetanib and Selpercatinib.
    Jazdarehee A; Abdel-Rahman O; Jacquier JE
    JCEM Case Rep; 2024 Feb; 2(2):luad174. PubMed ID: 38283729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Lloyd RV; Park JI
    Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in thyroid cancer: an extensive review of the literature.
    Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
    Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.
    Deshpande HA; Sheth K; Sosa JA; Roman S
    Clin Med Insights Oncol; 2012; 6():355-62. PubMed ID: 23133319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.